← Back to Clinical Trials
RecruitingPhase 4NCT05642806

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionChronic Rhinosinusitis With Nasal Polyps
SponsorSt. Paul's Sinus Centre
Study TypeINTERVENTIONAL
PhasePhase 4
Enrollment90
SexALL
Min Age19 Years
Max AgeN/A
Start Date2023-07-01
Completion2024-12-30
Interventions
MepolizumabPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab. A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.

Eligibility Criteria

Inclusion Criteria: 1. Are over the age of 19. 2. Patients with CRSwNP with or without asthma: * Asthma confirmed with a spirometry and assessment on previous history of asthma (a methacholine challenge test and atopy testing to document positive or negative history of asthma will be performed if there is no clinical record). * Presence or absence of nasal polyps. This can be based on formal exam at Baseline Visit or historical assessment. 3. Patients with CRSsNP with asthma: * These patients will not take the study treatment and they will only complete screening and baseline visits. 4. Females of childbearing potential must commit to using an acceptable method of birth control for the duration of the study and they must have a negative urine pregnancy test at each study visit. Exclusion Criteria: 1. Current or past sinonasal or bronchial tumours 2. Subjects who have been treated with oral antibiotics in the past month prior to surgery. 3. Subjects with known immunodeficiency 4. Subjec

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology